Pulmonary Fibrosis - Pipeline Review, H1 2016

  • ID: 3714987
  • Report
  • 380 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AdAlta Pty Ltd.
  • Bioneer Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hydra Biosciences, Inc.
  • Moerae Matrix, Inc.
  • Progenra, Inc.
  • MORE
Pulmonary Fibrosis - Pipeline Review, H1 2016

Summary

‘Pulmonary Fibrosis - Pipeline Review, H1 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AdAlta Pty Ltd.
  • Bioneer Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hydra Biosciences, Inc.
  • Moerae Matrix, Inc.
  • Progenra, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Pulmonary Fibrosis Overview

Therapeutics Development

Pipeline Products for Pulmonary Fibrosis - Overview

Pipeline Products for Pulmonary Fibrosis - Comparative Analysis

Pulmonary Fibrosis - Therapeutics under Development by Companies

Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes

Pulmonary Fibrosis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Pulmonary Fibrosis - Products under Development by Companies

Pulmonary Fibrosis - Products under Investigation by Universities/Institutes

Pulmonary Fibrosis - Companies Involved in Therapeutics Development

AdAlta Pty Ltd.

Advinus Therapeutics Ltd.

Aeolus Pharmaceuticals, Inc.

Afferent Pharmaceuticals, Inc.

AnaMar AB

Angion Biomedica Corp.

Antitope Limited

aTyr Pharma, Inc.

Biogen, Inc.

Bioneer Corporation

BiOrion Technologies B.V.

Bristol-Myers Squibb Company

Carolus Therapeutics, Inc.

Celgene Corporation

Chong Kun Dang Pharmaceutical Corp.

Clanotech AB

Compugen Ltd.

Cynata Therapeutics Limited

Diffusion Pharmaceuticals Inc.

Digna Biotech, S.L.

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Galapagos NV

Galectin Therapeutics, Inc.

GenKyoTex S.A.

GlaxoSmithKline Plc

Global Blood Therapeutics, Inc.

HanAll Biopharma Co., Ltd.

HEC Pharm Co., Ltd.

Histocell S.L.

Hydra Biosciences, Inc.

iBio, Inc.

Inventiva

Isarna Therapeutics GmbH

Kadmon Corporation, LLC

Kasiak Research Private Limited

KineMed, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lpath, Inc.

miRagen Therapeutics, Inc.

Moerae Matrix, Inc.

MorphoSys AG

NicOx S.A.

Novartis AG

Pacific Therapeutics Ltd.

Pharmaxis Limited

Pharmicell Co., Ltd.

Pluristem Therapeutics Inc.

Progenra, Inc.

Promedior, Inc.

ProMetic Life Sciences Inc.

Pulmatrix, Inc.

RedHill Biopharma Ltd.

Respira Therapeutics, Inc.

Rhizen Pharmaceuticals S.A.

Ribomic Inc.

Saje Pharma, LLC

Sanofi

SciFluor Life Sciences, LLC

Symic Biomedical, Inc.

TaiwanJ Pharmaceuticals Co., Ltd.

Teva Pharmaceutical Industries Limited

Therabron Therapeutics, Inc.

Vericel Corporation

Yuhan Corporation

Pulmonary Fibrosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(acetylcysteine + pentoxifylline) - Drug Profile

ABC-294640 - Drug Profile

acALY-18 - Drug Profile

AEOL-10150 - Drug Profile

AF-219 - Drug Profile

Altepan - Drug Profile

AM-0010 - Drug Profile

AMAP-102 - Drug Profile

Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile

Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile

BB-3 - Drug Profile

BG-00011 - Drug Profile

BMS-986020 - Drug Profile

BOT-191 - Drug Profile

CC-539 - Drug Profile

CC-90001 - Drug Profile

Cellgram-Lung - Drug Profile

CG-1011 - Drug Profile

CGEN-25009 - Drug Profile

CKD-942 - Drug Profile

CLT-28643 - Drug Profile

CM-101 - Drug Profile

CMYJH-01 - Drug Profile

CT-140 - Drug Profile

CT-2009 - Drug Profile

D-9030 - Drug Profile

DB-02901 - Drug Profile

disitertide - Drug Profile

Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile

FG-3019 - Drug Profile

GBT-1118 - Drug Profile

GBT-440 - Drug Profile

GKT-831 - Drug Profile

GLPG-1690 - Drug Profile

GRMD-02 - Drug Profile

GSK-3008348 - Drug Profile

HC-067047 - Drug Profile

HEC-00000585 - Drug Profile

HL-156FIB - Drug Profile

HR-017 - Drug Profile

IBIOCFB-03 - Drug Profile

ICG-001 - Drug Profile

iMod.Fc - Drug Profile

ISTH-0047 - Drug Profile

ITMN-10534 - Drug Profile

ITMN-14440 - Drug Profile

ITMN-30162 - Drug Profile

IVA-337 - Drug Profile

ixmyelocel-T - Drug Profile

JKB-117 - Drug Profile

JKB-119 - Drug Profile

KBP-7018 - Drug Profile

KD-025 - Drug Profile

lebrikizumab - Drug Profile

Lpathomab - Drug Profile

LT-0011 - Drug Profile

LTI-03 - Drug Profile

MGN-4220 - Drug Profile

MMI-0100 - Drug Profile

Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD - Drug Profile

MOR-107 - Drug Profile

NAS-911 - Drug Profile

NCX-466 - Drug Profile

Neumomir - Drug Profile

noscapine - Drug Profile

Oligonucleotides for Respiratory and Oncology - Drug Profile

OLX-201 - Drug Profile

omipalisib - Drug Profile

P-007 - Drug Profile

P-013 - Drug Profile

PB-01 - Drug Profile

PBF-1129 - Drug Profile

PBI-4050 - Drug Profile

PBI-4425 - Drug Profile

Peptide to Target C/EBP-Beta for Lung Fibrosis - Drug Profile

pirfenidone - Drug Profile

PLX-PAD - Drug Profile

PNQ-103 - Drug Profile

PRI-724 - Drug Profile

PRM-151 - Drug Profile

PUR-1500 - Drug Profile

PXS-4820 - Drug Profile

Q-122 - Drug Profile

RBM-005 - Drug Profile

RBM-006 - Drug Profile

Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile

Recombinant Peptides for Fibrosis - Drug Profile

Recombinant Protein for Inflammation and Pulmonary Fibrosis - Drug Profile

Refacell-IPF - Drug Profile

RES-529 - Drug Profile

RP-3128 - Drug Profile

RP-6503 - Drug Profile

RT-234 - Drug Profile

SAR-156597 - Drug Profile

SB-300 - Drug Profile

SD-560 - Drug Profile

SM-04646 - Drug Profile

Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile

Small Molecule to Inhibit MAPK for Pulmonary Fibrosis - Drug Profile

Small Molecules for COPD and IPF - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile

Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile

Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile

SPL-334 - Drug Profile

Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile

Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile

Stem Cell Therapy for Lung Fibrosis - Drug Profile

Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile

TD-139 - Drug Profile

tipelukast - Drug Profile

TM-5441 - Drug Profile

vismodegib - Drug Profile

YH-siRNA1 - Drug Profile

ZL-2102 - Drug Profile

Pulmonary Fibrosis - Recent Pipeline Updates

Pulmonary Fibrosis - Dormant Projects

Pulmonary Fibrosis - Discontinued Products

Pulmonary Fibrosis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pulmonary Fibrosis, H1 2016

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Investigation by Universities/Institutes, H1 2016

Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2016

Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016

Pulmonary Fibrosis - Pipeline by Antitope Limited, H1 2016

Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Biogen, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2016

Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016

Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016

Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2016

Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016

Pulmonary Fibrosis - Pipeline by Clanotech AB, H1 2016

Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H1 2016

Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016

Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H1 2016

Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2016

Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2016

Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016

Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2016

Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Inventiva, H1 2016

Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016

Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H1 2016

Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H1 2016

Pulmonary Fibrosis - Pipeline by KineMed, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2016

Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2016

Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2016

Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2016

Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016

Pulmonary Fibrosis - Pipeline by Ribomic Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H1 2016

Pulmonary Fibrosis - Pipeline by Sanofi, H1 2016

Pulmonary Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016

Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016

Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Vericel Corporation, H1 2016

Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016

Pulmonary Fibrosis - Dormant Projects, H1 2016

Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2016

Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2016

Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2016

Pulmonary Fibrosis - Dormant Projects (Contd..4), H1 2016

Pulmonary Fibrosis - Dormant Projects (Contd..5), H1 2016

Pulmonary Fibrosis - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Pulmonary Fibrosis, H1 2016

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AdAlta Pty Ltd.
Advinus Therapeutics Ltd.
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
AnaMar AB
Angion Biomedica Corp.
Antitope Limited
aTyr Pharma, Inc.
Biogen, Inc.
Bioneer Corporation
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Clanotech AB
Compugen Ltd.
Cynata Therapeutics Limited
Diffusion Pharmaceuticals Inc.
Digna Biotech, S.L.
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GlaxoSmithKline Plc
Global Blood Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Histocell S.L.
Hydra Biosciences, Inc.
iBio, Inc.
Inventiva
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
KineMed, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lpath, Inc.
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MorphoSys AG
NicOx S.A.
Novartis AG
Pacific Therapeutics Ltd.
Pharmaxis Limited
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics, Inc.
Rhizen Pharmaceuticals S.A.
Ribomic Inc.
Saje Pharma, LLC
Sanofi
SciFluor Life Sciences, LLC
Symic Biomedical, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Teva Pharmaceutical Industries Limited
Therabron Therapeutics, Inc.
Vericel Corporation
Yuhan Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll